Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Human DNA-PK activates a STING-independent DNA sensing pathway.

Burleigh K, Maltbaek JH, Cambier S, Green R, Gale M Jr, James RC, Stetson DB.

Sci Immunol. 2020 Jan 24;5(43). pii: eaba4219. doi: 10.1126/sciimmunol.aba4219.

PMID:
31980485
2.

Virtual-Reality Guided Versus Fluoroscopy-Guided Transseptal Puncture in a Cardiac Phantom.

James RC, Monsky WL, Jorgensen NW, Seslar SP.

J Invasive Cardiol. 2020 Feb;32(2):76-81. Epub 2020 Jan 20.

3.

Remodeling of Interstrand Crosslink Proximal Replisomes Is Dependent on ATR, FANCM, and FANCD2.

Huang J, Zhang J, Bellani MA, Pokharel D, Gichimu J, James RC, Gali H, Ling C, Yan Z, Xu D, Chen J, Meetei AR, Li L, Wang W, Seidman MM.

Cell Rep. 2019 May 7;27(6):1794-1808.e5. doi: 10.1016/j.celrep.2019.04.032.

4.

SemGen: a tool for semantics-based annotation and composition of biosimulation models.

Neal ML, Thompson CT, Kim KG, James RC, Cook DL, Carlson BE, Gennari JH.

Bioinformatics. 2019 May 1;35(9):1600-1602. doi: 10.1093/bioinformatics/bty829.

PMID:
30256901
5.

Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.

JAMA. 2016 Jul 5;316(1):40-50. doi: 10.1001/jama.2016.8655.

6.

Semantics-Based Composition of Integrated Cardiomyocyte Models Motivated by Real-World Use Cases.

Neal ML, Carlson BE, Thompson CT, James RC, Kim KG, Tran K, Crampin EJ, Cook DL, Gennari JH.

PLoS One. 2015 Dec 30;10(12):e0145621. doi: 10.1371/journal.pone.0145621. eCollection 2015.

7.

Evidence-based causation in toxicology: A 10-year retrospective.

James RC, Britt JK, Halmes NC, Guzelian PS.

Hum Exp Toxicol. 2015 Dec;34(12):1245-52. doi: 10.1177/0960327115601767. Review.

PMID:
26614812
8.

The Natural Product N-Palmitoyl-l-leucine Selectively Inhibits Late Assembly of Human Spliceosomes.

Effenberger KA, James RC, Urabe VK, Dickey BJ, Linington RG, Jurica MS.

J Biol Chem. 2015 Nov 13;290(46):27524-31. doi: 10.1074/jbc.M115.673210. Epub 2015 Sep 25.

9.

Tumors that mimic asbestos-related mesothelioma: time to consider a genetics-based tumor registry?

Kerger BD, James RC, Galbraith DA.

Front Genet. 2014 May 30;5:151. doi: 10.3389/fgene.2014.00151. eCollection 2014.

10.

Comments on recent discussions providing differing causation methodologies.

James RC, Britt J, Halmes NC, Guzelian PS.

Hum Exp Toxicol. 2014 Jan;33(1):109-12. doi: 10.1177/0960327113491511. Epub 2013 Jun 7. No abstract available.

PMID:
23749455
11.

Silver(I)-promoted conversion of thioamides to amidines: divergent synthesis of a key series of vancomycin aglycon residue 4 amidines that clarify binding behavior to model ligands.

Okano A, James RC, Pierce JG, Xie J, Boger DL.

J Am Chem Soc. 2012 May 30;134(21):8790-3. doi: 10.1021/ja302808p. Epub 2012 May 17.

12.

Redesign of glycopeptide antibiotics: back to the future.

James RC, Pierce JG, Okano A, Xie J, Boger DL.

ACS Chem Biol. 2012 May 18;7(5):797-804. doi: 10.1021/cb300007j. Epub 2012 Feb 21.

13.

Total synthesis of [Ψ[C(═S)NH]Tpg4]vancomycin aglycon, [Ψ[C(═NH)NH]Tpg4]vancomycin aglycon, and related key compounds: reengineering vancomycin for dual D-Ala-D-Ala and D-Ala-D-Lac binding.

Xie J, Okano A, Pierce JG, James RC, Stamm S, Crane CM, Boger DL.

J Am Chem Soc. 2012 Jan 18;134(2):1284-97. doi: 10.1021/ja209937s. Epub 2012 Jan 6.

14.

A redesigned vancomycin engineered for dual D-Ala-D-ala And D-Ala-D-Lac binding exhibits potent antimicrobial activity against vancomycin-resistant bacteria.

Xie J, Pierce JG, James RC, Okano A, Boger DL.

J Am Chem Soc. 2011 Sep 7;133(35):13946-9. doi: 10.1021/ja207142h. Epub 2011 Aug 16.

15.

Interventions to reduce the vasovagal reaction rate in young whole blood donors.

Tomasulo P, Kamel H, Bravo M, James RC, Custer B.

Transfusion. 2011 Jul;51(7):1511-21. doi: 10.1111/j.1537-2995.2011.03074.x. Epub 2011 Mar 7.

PMID:
21382043
16.

An oculoplastic use for the temporalis muscle flap.

Cehajic J, Moody A, James RC, Watson G, Wearne MJ.

Orbit. 2009;28(5):281-4. doi: 10.3109/01676830902856260. Review.

PMID:
19874120
17.

Delayed adverse reactions to blood donation.

Kamel H, Tomasulo P, Bravo M, Wiltbank T, Cusick R, James RC, Custer B.

Transfusion. 2010 Mar;50(3):556-65. doi: 10.1111/j.1537-2995.2009.02397.x. Epub 2009 Oct 5.

PMID:
19804573
18.

Clear path: towards an evidence-based toxicology (EBT).

Guzelian PS, Victoroff MS, Halmes C, James RC.

Hum Exp Toxicol. 2009 Feb;28(2-3):71-9. doi: 10.1177/0960327109102802. No abstract available.

PMID:
19713364
19.

Using multiple data features improved the validity of osteoporosis case ascertainment from administrative databases.

Lix LM, Yogendran MS, Leslie WD, Shaw SY, Baumgartner R, Bowman C, Metge C, Gumel A, Hux J, James RC.

J Clin Epidemiol. 2008 Dec;61(12):1250-60. doi: 10.1016/j.jclinepi.2008.02.002. Epub 2008 Jul 10.

PMID:
18619800
20.

Development of a neurotoxic equivalence scheme of relative potency for assessing the risk of PCB mixtures.

Simon T, Britt JK, James RC.

Regul Toxicol Pharmacol. 2007 Jul;48(2):148-70. Epub 2007 Mar 31.

PMID:
17475378
21.

Evidence-based toxicology: a comprehensive framework for causation.

Guzelian PS, Victoroff MS, Halmes NC, James RC, Guzelian CP.

Hum Exp Toxicol. 2005 Apr;24(4):161-201. Review.

PMID:
15957536
22.

Trichloroethylene and cancer in humans: recognizing the need for an evidence based analysis.

Garabrant DH, James RC.

Toxicology. 2005 Aug 15;212(1):80-4. No abstract available.

PMID:
15949887
23.

A model for non-communicable disease surveillance in Canada: the prairie pilot diabetes surveillance system.

James RC, Blanchard JF, Campbell D, Clottey C, Osei W, Svenson LW, Noseworthy TW.

Chronic Dis Can. 2004 Winter;25(1):7-12.

PMID:
15298483
24.

Development of an oral cancer slope factor for Aroclor 1268.

Warren DA, Kerger BD, Britt JK, James RC.

Regul Toxicol Pharmacol. 2004 Aug;40(1):42-53.

PMID:
15265605
25.
26.

Incident cerebrovascular disease in rural and urban Alberta.

Yiannakoulias N, Svenson LW, Hill MD, Schopflocher DP, Rowe BH, James RC, Wielgosz AT, Noseworthy TW.

Cerebrovasc Dis. 2004;17(1):72-8. Epub 2003 Oct 6.

PMID:
14534379
27.

Regional comparisons of inpatient and outpatient patterns of cerebrovascular disease diagnosis in the province of Alberta.

Yiannakoulias N, Svenson LW, Hill MD, Schopflocher DP, James RC, Wielgosz AT, Noseworthy TW.

Chronic Dis Can. 2003 Winter;24(1):9-16.

PMID:
12757631
28.

Evaluation of the carcinogenicity of 1,1-dichloroethylene (vinylidene chloride).

Roberts SM, Jordan KE, Warren DA, Britt JK, James RC.

Regul Toxicol Pharmacol. 2002 Feb;35(1):44-55. Review.

PMID:
11846635
29.
30.

Excess costs of diabetes in the Aboriginal population of Manitoba, Canada.

Jacobs P, Blanchard JF, James RC, Depew N.

Can J Public Health. 2000 Jul-Aug;91(4):298-301.

31.

Soil ingestion: a concern for acute toxicity in children.

Calabrese EJ, Stanek EJ, James RC, Roberts SM.

Environ Health Perspect. 1997 Dec;105(12):1354-8.

32.

Complications, comorbidities, and mortality: improving classification and prediction.

Roos LL, Stranc L, James RC, Li J.

Health Serv Res. 1997 Jun;32(2):229-38; discussion 239-42.

33.

Adrenergic modulation of hepatotoxicity.

Roberts SM, DeMott RP, James RC.

Drug Metab Rev. 1997 Feb-May;29(1-2):329-53. Review.

PMID:
9187524
34.

Analysis of blood donor return behaviour using survival regression methods.

James RC, Matthews DE.

Transfus Med. 1996 Mar;6(1):21-30.

PMID:
8696444
35.

Influence of soil half-life on risk assessment of carcinogens.

Borgert CJ, Roberts SM, Harbison RD, James RC.

Regul Toxicol Pharmacol. 1995 Oct;22(2):143-51. Review.

PMID:
8577949
36.

Hepatitis C virus transmission by intravenous immunoglobulin.

James RC, Mosley JW.

Lancet. 1995 Aug 5;346(8971):374; author reply 374-5. No abstract available.

PMID:
7542719
37.

Using the EPC approach to develop health-based soil and water screening concentrations for environmental chemicals.

Williams CA, James RC, Freeman RW.

Regul Toxicol Pharmacol. 1995 Aug;22(1):64-75.

PMID:
7494905
38.

Mechanistic studies on the potentiation of carbon tetrachloride hepatotoxicity by methamphetamine.

Roberts SM, Harbison RD, James RC.

Toxicology. 1995 Mar 31;97(1-3):49-57.

PMID:
7716792
39.

Exacerbation of carbon tetrachloride-induced liver injury in the rat by methamphetamine.

Roberts SM, Harbison RD, Westhouse RA, James RC.

Toxicol Lett. 1995 Feb;76(1):77-83.

PMID:
7701520
40.

The EPC approach to estimating safety from exposure to environmental chemicals.

Williams CA, Jones HD, Freeman RW, Wernke MJ, Williams PL, Roberts SM, James RC.

Regul Toxicol Pharmacol. 1994 Dec;20(3 Pt 1):259-80.

PMID:
7724834
41.

Methamphetamine potentiation of carbon tetrachloride hepatotoxicity in mice.

Roberts SM, Harbison RD, James RC.

J Pharmacol Exp Ther. 1994 Nov;271(2):1051-7.

PMID:
7965767
42.

Methylphenidate-induced hepatotoxicity in mice and its potentiation by beta-adrenergic agonist drugs.

Roberts SM, Harbison RD, Roth L, James RC.

Life Sci. 1994;55(4):269-81.

PMID:
7913199
43.

Inhibition by ethanol of the metabolism of cocaine to benzoylecgonine and ecgonine methyl ester in mouse and human liver.

Roberts SM, Harbison RD, James RC.

Drug Metab Dispos. 1993 May-Jun;21(3):537-41.

PMID:
8100512
44.

Polychlorinated biphenyl exposure and human disease.

James RC, Busch H, Tamburro CH, Roberts SM, Schell JD, Harbison RD.

J Occup Med. 1993 Feb;35(2):136-48. Review.

PMID:
8433185
45.

Phenylpropanolamine potentiation of acetaminophen-induced hepatotoxicity: evidence for a glutathione-dependent mechanism.

James RC, Harbison RD, Roberts SM.

Toxicol Appl Pharmacol. 1993 Feb;118(2):159-68.

PMID:
8382844
46.
47.

Cocaethylene hepatotoxicity in mice.

Roberts SM, Roth L, Harbison RD, James RC.

Biochem Pharmacol. 1992 May 8;43(9):1989-95.

PMID:
1596286
48.

Cocaine hepatotoxicity: influence of hepatic enzyme inducing and inhibiting agents on the site of necrosis.

Roth L, Harbison RD, James RC, Tobin T, Roberts SM.

Hepatology. 1992 May;15(5):934-40.

PMID:
1568735
49.

An assay for cocaethylene and other cocaine metabolites in liver using high-performance liquid chromatography.

Roberts SM, Munson JW, James RC, Harbison RD.

Anal Biochem. 1992 May 1;202(2):256-61.

PMID:
1519750
50.

Potentiation of carbon tetrachloride hepatotoxicity by phenylpropanolamine.

Roberts SM, Harbison RD, Seng JE, James RC.

Toxicol Appl Pharmacol. 1991 Nov;111(2):175-88.

PMID:
1957308

Supplemental Content

Loading ...
Support Center